English summaries translate the Chinese website. Links open the original source articles, which may be in Chinese.
R&D progress, marketing approval, cooperation and announcements - read Bio-Thera's latest public information by time.
Bio-Thera Solutions, Ltd. (stock code: 688177, hereinafter referred to as "Bio-Thera" or the "Company") is a global biopharmaceutical company headquartered in Guangzhou, China, based on science and innovation. The company's independently developed bevacizumab injection (trade name: Pubeixi®) was officially approved by the National Medical Products Administration (NMPA), adding...
Read more
Bio-Thera Solutions, Ltd. (SSE code: 688177) is a science-based and innovative global biopharmaceutical company (hereinafter referred to as "Bio-Thera" or the "Company") located in Guangzhou, China. The company announced today that it has entered into cooperation with Avalon Pharmaceuticals (hereinafter referred to as "Avalon") regarding BAT2...
Bio-Thera Solutions, Ltd. (SSE code: 688177) is a science-based and innovative global biopharmaceutical company (hereinafter referred to as "Bio-Thera" or the "Company") located in Guangzhou, China. The company announced today that its self-developed antibody-drug conjugates BAT8013 (CD25 ADC) has recently been tested for late-stage or metastatic...
Bio-Thera Solutions, Ltd. (Shanghai Stock Exchange Code: 688177) is a global biopharmaceutical company based on science and innovation based in Guangzhou, China, hereinafter referred to as "Bio-Thera" or the "Company". The European Society for Medical Oncology Annual Meeting (ESMO 2026) will be held in Madrid, Spain, from October 23 to October 27, 2026...
Bio-Thera Solutions, Ltd. (stock code: 688177) is a global biopharmaceutical company based on science and innovation based in Guangzhou, China, hereinafter referred to as "Bio-Thera" or the "Company". The company is committed to developing a new generation of innovative drugs and biosimilars for the treatment of tumors, autoimmune diseases, cardiovascular diseases, ophthalmology and other threats to human...
Bio-Thera Solutions, Ltd. (stock code: 688177) is a global, science-based and innovative biopharmaceutical company headquartered in Guangzhou, China (hereinafter referred to as "Bio-Thera" or the "Company"). The company's partner Organon LLC (hereinafter referred to as "Organon") recently received approval from the U.S. Food and Drug Administration...
Bio-Thera Solutions, Ltd. (stock code: 688177) is a global, science-based and innovative biopharmaceutical company headquartered in Guangzhou, China (hereinafter referred to as "Bio-Thera" or the "Company"). The company recently received notification from the Health Sciences Authority of Singapore (HSA) that a drug developed by Bio-Thera with reference to ustekinumab (trade name: Stelara®)...
Bio-Thera Solutions, Ltd. (stock code: 688177) is an innovative global biopharmaceutical company based on science (hereinafter referred to as "Bio-Thera" or the "Company"). Recently, the company demonstrated BAT2506, a biopharmaceutical developed with reference to Golimumab, at the 2026 European Congress of Rheumatology (EULAR)...
Bio-Thera Solutions, Ltd. (stock code: 688177) is an innovative global biopharmaceutical company based on science (hereinafter referred to as "Bio-Thera" or the "Company"). Recently, at the 2026 American Society of Clinical Oncology (ASCO) annual meeting, academician Song Erwei from Sun Yat-sen Memorial Hospital of Sun Yat-sen University and Zhou Qi from Chongqing University Cancer Hospital...
